| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BeOne Medicines Ltd. | Tislelizumab and chemotherapy - (RATIONALE 304) | Non-squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Tislelizumab and chemoradiotherapy | Esophageal squamous cell carcinoma (ESCC) | Phase 3 | Trial Completed | Intravenous | Oncology |
| BeOne Medicines Ltd. | DKN-01 and Tislelizumab - (DisTinGuish) | Gastric / Gastroesophageal Junction Cancer | Phase 2a | Data Released | Intravenous | Oncology |
| BeOne Medicines Ltd. | Tislelizumab and chemotherapy - (RATIONALE 304) | Non-squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Pamiparib (BGB-290) | Gastric Cancer | Phase 2 | Oral | Oncology | |
| BeOne Medicines Ltd. | Tislelizumab and chemoradiotherapy | Esophageal squamous cell carcinoma (ESCC) | Phase 3 | Trial Completed | Intravenous | Oncology |
| BeyondSpring Inc. | Plinabulin with pegfilgrastim | Multiple Myeloma | Phase 2 | Intravenous | Oncology | |
| BeyondSpring Inc. | Plinabulin + G-CSF Combination - (PROTECTIVE-1) | Docetaxel-induced neutropenia in breast cancer | Phase 2/3 | Intravenous | Oncology |